Form 4: Casdin Capital Reports Purchase of GeneDx Holdings Corp. Shares

Casdin Capital, a significant shareholder in GeneDx Holdings Corp., has reported the acquisition of 40,000 shares of Class A Common Stock at an average price of $21.0651.

Summary

• On May 29, 2024, Casdin Capital, along with related entities and individuals, reported transactions in GeneDx Holdings Corp. (WGS) Class A Common Stock.
• Casdin Capital purchased 40,000 shares at a weighted average price of $21.0651, with individual transactions ranging from $20.9752 to $21.1876.
• Following the reported transaction, Casdin Partners Master Fund, L.P. directly owns 2,963,509 shares.
• Eli Casdin directly owns 3,142 shares.
• Casdin Partners FO1-MSV, LP directly owns 432,902 shares.
• CMLS Holdings LLC directly owns 333,144 shares.
• The reporting parties disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a report of stock transactions, with no explicit positive or negative commentary. The purchase could be seen as a positive signal, but it's not definitive.

Positives

• The purchase of additional shares by a major shareholder could be interpreted as a sign of confidence in the company's future prospects.

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing reflects ongoing investment activity in the genomics and diagnostics sector, where GeneDx operates.

Stakeholder Impact

• The purchase of shares by a major shareholder may have a positive impact on shareholder confidence.

Key Dates